On the other hand, although SIRPα is known to block the activation and survival of dendritic cells, mainly through sequestration of the PI3K p85 subunit [17, 21], treatment with the anti-SIRPα antibody did not lead to an appreciable increase of dendritic cells in pancreatic tumor tissue, if not in combination with the anti-BAG3 antibody (Fig. 5). Here, SIRPA is linked to pancreatic neoplasm.